YOLFTbeta
EyePoint, Inc

EyePoint, Inc

EYPT · NASDAQ · Healthcare / Biotechnology

0.31USD-0.01 (-2.97%)

Price History

Full chart

Market Stats

Previous Close0.3195
Open0.33
Day Range0.31 – 0.33
52-Week Range3.42 – 19.11
Volume3.05M
Market Cap312.09M
P/E (TTM)0.00
Forward P/E6.16
EPS-3.75
Dividend Yield0.00%
Beta1.64
50-Day Avg8.16
200-Day Avg12.94

About

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Jay S. Duker M.D.
  • Employees214
  • Headquarters480 Pleasant Street, Watertown, MA, United States, 02472, USA
  • Websitehttps://eyepoint.bio

Leadership

  • Dr. Jay S. Duker M.D.President, CEO & Director · b. 1959
  • Mr. George O. Elston CPAExecutive VP & CFO · b. 1965
  • Dr. Ramiro Ribeiro M.D., Ph.D.Chief Medical Officer · b. 1983
  • Dr. Marcia Sellos-Moura Ph.D.Chief Scientific Officer
  • Mr. Ron I. Honig Esq.Chief Legal Officer & Company Secretary
  • Ms. Jennifer LeonardChief People Officer & Senior VP of IT
  • Mr. David Scott Jones M.A.Senior Vice President · b. 1968
  • Ms. Isabelle LefebvreChief Regulatory Officer
  • Mr. Michael J. MaciocioChief Manufacturing Officer
  • Mr. Michael CampbellChief Commercial Officer

Financials

Income Statement

Currency: USD2001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue516.32K265.23K624.28K629.52K1.04M1.78M3.48M12.16M23.05M4.96M3.53M2.14M3.47M26.57M26.57M1.62M7.54M5.86M20.36M34.44M36.94M41.40M46.02M43.27M31.37M
Growth (%)--48.63%+135.37%+0.84%+64.57%+72.30%+94.73%+249.88%+89.55%-78.46%-28.98%-39.22%+62.06%+664.90%0.00%-93.90%+365.37%-22.32%+247.76%+69.10%+7.27%+12.09%+11.14%-5.97%-27.50%
Cost of Revenue----20.44M11.01M24.09M13.36M3.33M3.35M7.04M7.00M9.57M12.09M14.38M14.88M16.18M18.50M2.69M5.82M8.18M8.33M4.63M3.71M2.07M
Gross Profit516.32K265.23K629.52K629.52K1.47M-9.23M3.48M12.16M19.73M1.61M3.53M-4.86M-6.10M14.48M26.57M1.62M7.54M-13.93M17.68M28.61M28.76M33.08M41.39M39.56M29.30M
Gross Margin100.00%100.00%100.84%100.00%141.45%-517.03%100.00%100.00%85.57%32.43%100.00%-226.88%-175.64%54.50%100.00%100.00%100.00%-237.89%86.81%83.09%77.86%79.89%89.93%91.42%93.41%
Operating Expense1.80M6.50M15.18M10.88M53.90M21.25M28.38M16.80M10.64M11.61M13.91M7.17M7.39M8.06M20.14M23.39M26.11M35.19M65.54M65.90M84.04M132.72M116.45M185.41M272.74M
Operating Income-1.28M-6.24M-14.55M-10.25M-52.44M-30.48M-24.90M-4.64M9.09M-10.00M-10.38M-12.03M-13.49M6.42M6.42M-21.77M-18.58M-49.12M-47.86M-37.29M-55.28M-99.64M-75.07M-145.85M-243.43M
Operating Margin-247.68%-2351.37%-2330.58%-1628.79%-5061.39%-1707.79%-716.37%-38.12%39.44%-201.47%-294.41%-561.41%-388.42%24.17%24.17%-1344.07%-246.40%-838.76%-235.02%-108.28%-149.64%-240.65%-163.13%-337.06%-775.98%
EBITDA-1.28M-6.00M-9.44M-7.78M-43.43M-19.47M-24.90M-1.20M12.42M-6.65M-8.15M-11.04M-12.65M7.30M7.30M-20.87M-17.76M-46.47M-48.01M-35.49M-50.15M-96.62M-69.00M-129.23M-229.34M
EBITDA Margin-247.68%-2260.53%-1511.71%-1235.68%-4192.18%-1090.76%-716.37%-9.85%53.86%-133.90%-231.25%-515.03%-364.27%27.49%27.49%-1288.02%-235.59%-793.48%-235.76%-103.05%-135.76%-233.36%-149.94%-298.63%-731.06%
Net Income-2.25M-2.56M-12.75M-11.18M-46.96M-84.84M-75.67M-2.51M8.75M-8.63M-24.84M-11.90M-13.36M6.35M6.35M-21.55M-18.48M-53.17M-56.79M-45.39M-58.42M-102.25M-70.80M-130.87M-231.96M
Net Income Margin-436.07%-965.00%-2042.88%-1776.47%-4532.53%-4753.11%-2176.93%-20.65%37.97%-173.78%-704.34%-555.30%-384.54%23.89%23.89%-1330.06%-245.19%-907.97%-278.88%-131.82%-158.14%-246.97%-153.84%-302.43%-739.42%
R&D1.80M3.08M4.87M6.29M6.29M11.70M20.03M14.43M8.01M6.99M7.04M7.04M9.57M9.57M12.09M14.38M14.88M20.82M15.37M17.42M28.50M49.64M64.66M132.93M221.04M
R&D as % of Total Revenue347.68%1161.64%780.49%999.78%607.51%655.58%576.24%118.62%34.73%140.87%199.63%328.46%275.64%36.04%45.50%887.72%197.37%355.60%75.46%50.60%77.15%119.90%140.51%307.18%704.60%
Interest Expense03.92K3.92K03.37M9.49M507.00K507.00K013.00K1.00K02.00K1.00K00720.00K720.00K6.18M7.26M5.50M3.19M1.25M14.00K33.00K
Interest Expense % of Total Revenue0.00%1.48%0.63%0.00%325.67%531.71%14.59%4.17%0.00%0.26%0.03%0.00%0.06%0.00%0.00%0.00%9.55%12.30%30.33%21.07%14.88%7.70%2.71%0.03%0.11%

Balance Sheet

Currency: USD2000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets4.72M-4.82M69.76M62.30M62.30M97.60M55.78M39.23M43.01M47.11M20.60M16.25M22.67M32.37M32.37M18.68M18.68M71.67M72.97M91.72M263.37M180.36M355.18M418.46M364.00M
Total Liabilities145.74K-588.38K1.35M1.56M1.56M31.40M25.71M17.44M9.97M9.68M6.96M8.55M7.75M9.00M10.74M5.34M5.34M59.98M64.64M73.18M78.99M83.99M88.86M81.96M57.88M
Total Equity4.57M-4.09M25.60M60.74M60.74M66.20M30.08M21.79M33.04M37.43M13.64M7.70M14.92M23.37M20.88M13.34M13.34M11.69M8.33M18.54M184.38M96.37M266.32M336.50M306.11M
Cash1.64M-792.81K21.79M9.79M9.79M4.25M15.61M9.85M15.51M12.91M4.63M6.90M15.33M19.12M15.31M16.90M16.90M38.78M22.21M44.91M178.59M95.63M281.26M99.70M101.82M
Total Debt145.74K----11.26M9.07M----------17.31M17.65M50.60M46.42M39.20M46.35M4.91M21.86M22.79M
Net Debt-1.50M--792.81K-21.79M-9.79M-9.79M4.82M-2.67M-9.85M-6.90M-15.51M-12.91M-4.63M-6.90M-15.33M-19.12M-15.31M411.00K-21.47M28.39M-4.60M-139.39M-49.28M-276.36M-77.85M-79.03M

Cash Flow

Currency: USD2002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-3.06M-5.44M-9.34M-9.34M-21.35M-21.21M-5.14M9.90M9.90M-3.17M-9.00M-8.74M10.30M10.30M-16.32M-20.49M-21.91M-56.70M-14.44M-50.10M-65.00M1.88M-126.23M-240.11M
Investing Cash Flow-34.90K-366.33K--4.13M-4.13M1.77M-259.00K-2.07M-9.50M606.00K6.36M66.00K66.00K-4.46M13.58M-16.89M-16.89M-213.00K-362.00K-33.12M-17.27M-3.31M-219.35M68.58M
Financing Cash Flow572.75K2.76M2.76M21.94M21.65M18.39M18.39M802.00K10.06M10.06M4.67M19.04M19.04M16.99M8.50M8.50M29.20M33.86M37.49M216.90M-690.00K187.07M164.02M173.65M
Capital Expenditure35.58K366.33K2.59M2.59M1.15M82.00K272.00K195.00K15.00K133.00K405.00K68.00K248.00K161.00K113.00K147.00K108.00K213.00K362.00K156.00K2.15M3.48M4.05M3.28M
Free Cash Flow-3.10M-5.80M-11.93M-11.93M-17.29M-21.30M-5.42M-8.63M9.88M-3.30M-9.41M-8.81M-10.92M10.14M-16.43M-20.64M-22.02M-56.91M-14.80M-50.25M-67.16M-1.61M-130.28M-243.39M
Dividends Paid---------0000000--------
FCF to OCF101.16%106.74%127.71%127.71%81.01%100.39%105.29%-87.19%99.85%104.20%104.50%100.78%-106.04%98.44%100.69%100.72%100.49%100.38%102.51%100.31%103.31%-85.76%103.21%101.37%
Dividend Paid to FCF---------0.00%0.00%0.00%0.00%0.00%0.00%0.00%--------

Earnings

Report DateSep 30, 2007Dec 31, 2007Mar 31, 2008Jun 30, 2008Nov 11, 2008Feb 11, 2009May 13, 2009Sep 25, 2009Nov 13, 2009Feb 11, 2010May 12, 2010Sep 22, 2010Nov 5, 2010Feb 9, 2011May 10, 2011Sep 12, 2011Nov 7, 2011Feb 8, 2012May 9, 2012Sep 24, 2012Nov 8, 2012Feb 6, 2013May 13, 2013Sep 25, 2013Nov 12, 2013Feb 7, 2014May 13, 2014Sep 9, 2014Nov 7, 2014Feb 5, 2015May 8, 2015Sep 9, 2015Nov 5, 2015Feb 8, 2016May 5, 2016Sep 12, 2016Nov 7, 2016Feb 7, 2017May 4, 2017Sep 11, 2017Nov 7, 2017Feb 7, 2018May 8, 2018Sep 12, 2018Nov 6, 2018Mar 14, 2019May 8, 2019Aug 7, 2019Nov 7, 2019Mar 5, 2020May 6, 2020Aug 5, 2020Nov 5, 2020Mar 4, 2021May 5, 2021Aug 4, 2021Nov 3, 2021Mar 3, 2022May 4, 2022Aug 3, 2022Nov 2, 2022Mar 2, 2023May 3, 2023Aug 2, 2023Nov 1, 2023Mar 7, 2024May 8, 2024Aug 7, 2024Nov 7, 2024Mar 5, 2025May 7, 2025Aug 6, 2025Nov 5, 2025Mar 5, 2026May 6, 2026Aug 5, 2026Nov 4, 2026
EPS Estimate----------0.20-1.906.20-1.454.50-2.15-1.80-2.10-1.75-1.75-1.90-1.00-1.30-1.30-1.20-1.50-1.30-1.50-1.60-1.20-1.27-1.27-1.35-1.50-1.50-1.95-1.25-1.90-1.83-1.50-1.50-1.50-1.50-1.20-1.40-1.47-1.40-1.37-1.20-1.37-1.17-0.95-1.05-0.30-0.17-0.50-0.45-0.40-0.53-0.59-0.55-0.69-0.61-0.650.37-0.51-0.49-0.42-0.51-0.54-0.48-0.69-0.80-0.77-0.75-0.81-0.92-0.81
EPS Actual-1.78-12.70-12.05-35.00-0.26-0.48-0.35-0.29-0.87-0.01-1.506.80-1.70-1.50-1.30-0.10-1.20-1.30-1.30-1.10-1.10-1.10-1.20-1.70-1.40-1.33-0.79-1.366.70-1.40-1.70-1.70-1.70-1.80-1.50-1.90-2.10-0.00-1.50-1.60-1.50-1.30-1.02-1.89-1.90-1.20-1.60-1.10-1.50-1.00-1.10-1.00-0.30-1.00-0.50-0.42-0.58-0.59-0.52-0.52-0.49-1.16-0.56-0.61-0.33-0.33-0.55-0.58-0.54-0.64-0.65-0.85-0.85-0.81-0.99-1.09-
Surprise---------93.45%21.05%9.68%-17.24%-133.33%39.53%94.44%42.86%25.71%25.71%42.11%-10.00%15.38%7.69%-41.67%6.67%-2.31%47.33%15.00%658.33%-10.24%-33.86%-25.93%-13.33%-20.00%23.08%-52.00%-10.53%99.89%0.00%-6.67%0.00%13.33%15.00%-35.00%-29.25%14.29%-16.79%8.33%-9.49%14.53%-15.79%4.76%0.00%-488.24%0.00%6.67%-45.00%-11.32%11.86%5.45%28.99%-90.16%13.85%-264.86%35.29%32.65%-30.95%-13.73%0.00%-34.31%5.80%-6.25%-10.39%-8.33%-22.22%-18.48%-
Timing---------After-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-After-hoursAfter-hoursPre-market-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap312.09M
Enterprise Value160.05M
Trailing P/E0.00
Forward P/E6.16
Price / Sales108.86
Price / Book2.11
EPS-3.75
Book Value0.396
Revenue (TTM)2.79M
Gross Profit (TTM)-257.47M
EBITDA-314.38M
Profit Margin0.00%
Operating Margin-19207.10%
Return on Equity-148.70%
Return on Assets-74.85%
Shares Outstanding86.21M
Shares Float60.67M
Beta1.64
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 13 analystsTarget 25.91
  • Strong Buy
    9
  • Buy
    4

Ownership Breakdown

Institutions
117.66%
Insiders
3.52%
Retail / Other
0.00%

Top Institutional Holders

  • Suvretta Capital Management, LLC
    8.30M9.62%
  • Cormorant Asset Management, LLC
    8.27M9.59%
  • BlackRock Inc
    7.18M8.33%
  • Federated Hermes Inc
    5.68M6.59%
  • Franklin Templeton Inc
    5.05M5.86%
  • Adage Capital Partners Gp LLC
    4.83M5.60%
  • HHG PLC
    3.60M4.18%
  • Vanguard Capital Management, LLC
    3.56M4.13%
  • Paradigm Biocapital Advisors LP
    2.89M3.35%
  • COMMODORE CAPITAL LP
    2.83M3.28%
  • State Street Corp
    2.10M2.43%
  • Aberdeen Group PLC
    2.01M2.33%
  • Geode Capital Management, LLC
    1.98M2.30%
  • Citadel Advisors Llc
    1.98M2.29%
  • StemPoint Capital LP
    1.62M1.88%

Top Fund Holders

  • Federated Hermes Kaufmann R
    2.77M3.21%
  • Vanguard MStar Total Stk Mkt Idx Invest
    2.64M3.07%
  • Franklin Biotechnology Discv A(acc)USD
    2.08M2.41%
  • iShares Russell 2000 ETF
    1.99M2.31%
  • Federated Hermes Kaufmann Small Cap A
    1.98M2.30%

Stock Splits

  • Dec 9, 20201:10
  • Jun 11, 20081:4